Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • zwerp2000 zwerp2000 Jun 14, 2013 6:21 AM Flag

    Leerink remains cautious on accelerated approval for Sarepta

    Leerink remains cautious on accelerated approval for Sarepta
    Leerink continues to believe the FDA may be reluctant to approve Sarepta's eteplirsen on the Phase II data alone. The firm says Sarepta expects to meet with the FDA in Q3 and update investors thereafter. It thinks an announcement that an additional study is needed for approval could send the stock lower. Leerink reiterates a Market Perform rating on Sarepta.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Leerink is sounding silly because they're just making repetitive comments like Maxim Group was doing for FSLR when it was in the 20s and 30s. They kept saying they were cautious with a target of 9. Now they're cautious with a target of 42! LOL.

      Sentiment: Strong Buy

    • Z

      reliable word is that Leerink has clients who are now short Srpt

      those clients were long, took their profit and then flipped short

      I am sure that the timing of the Leerink update to be ONE DAY after the activist/FDA meeting is NOT a coincidence

      the Leerink report does not disclose a single shred of new info, and rather, merely is to remind readers that Leerink is bearish on AA

      as we know, this IS the short thesis when reduced down to 4 words

    • Leerink is helping the Prosensa IPO, look for these bookers to talk dirty about SRPT right here. Look at the F-1 filing of Prosensa, it said repeatedly that if SRPT get AA, it will be a significant risk to them. These bookers are trying to get investors to buy the Prosensa IPO, so they have to talk down the risk SRPT AA. It is just a game. Leerink was +ve SRPT for so long, and all of sudden, it went -ve to mkt perform. Why? Because it is part of the Prosensa IPO? Let me tell you, the biggest risk to SRPT is Prosensa and its gawd awful heartless big pharma partner fooouck up the P3 trial and get a -ve 6mwt outcome. This could panic the whole exon skip approach of DMD therapy, including suspicion of Etep's efficacy. That would be a disastrous outcome for the DMD community.

 
SRPT
13.41-0.01(-0.07%)11:29 AMEDT